# US 2024/0002883 A1 · Viral vector-producing cells having improved ability to produce vector, method for producing same and method for selecting same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002883 A1
- Document ID: US20240002883A1
- Status: Published application
- Kind: A1
- Application number: 18/340,593
- Filed: 2023-06-23
- Published: 2024-01-04
- Earliest claimed: 2020-12-25
- Assignees: AGC Inc.
- Applicants: Agc Inc.
- Inventors: Chinatsu MORIYAMA; Yasuhiro KAWANO; Kana TANABE; Susumu KUBOTA; Megumi KISHIMOTO
- Web page: https://patentgrep.com/patent/US20240002883A1

## CPC

- C12N 15/86: Viral vectors
- C07K 14/47: from mammals
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Viral vector-producing cells with improved ability to produce viral vector, a production method thereof, a kit containing the same, a method for selecting viral vector-producing cells, and the like are provided. A viral vector-producing cell in which the expression of a protein derived from the viral vector-producing cell is regulated, specifically, the expression of the aforementioned protein is regulated as compared with that in the viral vector-producing cells before regulation of the expression or HEK293 cells (Accession number ATCC CRL1573) shows an improved ability to produce viral vectors.

## Claims

### Claim 1

A viral vector-producing cell with an improved ability to produce vectors, wherein expression of a protein derived from the viral vector-producing cell in the cell is regulated.

### Claim 2 (depends on 1)

The viral vector-producing cell according to claim 1, wherein the expression of the protein derived from the viral vector-producing cell is regulated as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in HEK293 cell (Accession number ATCC CRL1573).

### Claim 3 (depends on 1)

The viral vector-producing cell according to claim 1, wherein the aforementioned expression of the protein derived from the viral vector-producing cell is increased as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in HEK293 cell (Accession number ATCC CRL1573).

### Claim 4 (depends on 3)

The viral vector-producing cell according to claim 3, wherein the aforementioned expression of the protein derived from the viral vector-producing cell is increased 1.5 times or more at the time of viral vector production, as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in HEK293 cell (Accession number ATCC CRL1573).

### Claim 5 (depends on 3)

The viral vector-producing cell according to claim 3, wherein the increase in the aforementioned expression of the protein derived from the viral vector-producing cell is achieved by addition of an additive to the cell, or by introducing an exogenous plasmid into the viral vector-producing cell.

### Claim 6 (depends on 3)

The viral vector-producing cell according to claim 3, wherein the aforementioned protein derived from viral vector-producing cell is at least one type selected from the group consisting of PIK3C2A, UBE2C, ASNS, NIFK, PDCD4, DDX47, GTPBP4, FTSJ3, DDX49, GNL2, NAT10, UBL5, SERBP1, and NOVA2.

### Claim 7 (depends on 1)

The viral vector-producing cell according to claim 1, wherein the aforementioned expression of the protein derived from the viral vector-producing cell is decreased as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in HEK293 cell (Accession number ATCC CRL1573).

### Claim 8 (depends on 7)

The viral vector-producing cell according to claim 7, wherein the aforementioned expression of the protein derived from the viral vector-producing cell is decreased by not less than 10% at the time of viral vector production, as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in HEK293 cell (Accession number ATCC CRL1573).

### Claim 9 (depends on 7)

The viral vector-producing cell according to claim 7, wherein the decrease in the aforementioned expression of the protein derived from the viral vector-producing cell is achieved by addition of an additive to the cell, or by introducing an exogenous plasmid into the viral vector-producing cell.

### Claim 10 (depends on 7)

The viral vector-producing cell according to claim 7, wherein the aforementioned protein derived from viral vector-producing cell is at least one type selected from the group consisting of ISG15, CD44, LMNA, ACP2 and MRE11.

### Claim 11 (depends on 1)

The viral vector-producing cell according to claim 1, which is derived from a human cell.

### Claim 12 (depends on 11)

The viral vector-producing cell according to claim 11, wherein the aforementioned human cell is HEK293 cell.

### Claim 13 (depends on 1)

The viral vector-producing cell according to claim 1, wherein the aforementioned viral vector is an adeno-associated viral vector.

### Claim 14

A method for producing a viral vector-producing cell with an improved ability to produce vectors, comprising regulating expression of a protein derived from the viral vector-producing cell in the viral vector-producing cell.

### Claim 15 (depends on 14)

The production method according to claim 14, wherein the regulation is to regulate the expression of the aforementioned protein by comparison with the viral vector-producing cell before regulation, or HEK293 cell (Accession number ATCC CRL1573).

### Claim 16 (depends on 14)

The production method according to claim 14, wherein the regulation is to increase the aforementioned expression of the protein derived from the viral vector-producing cell as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or HEK293 cell (Accession number ATCC CRL1573).

### Claim 17 (depends on 16)

The production method according to claim 16, wherein the regulation is to increase the aforementioned expression of the protein derived from the viral vector-producing cell 1.5 times or more at the time of viral vector production, as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or HEK293 cell (Accession number ATCC CRL1573).

### Claim 18 (depends on 16)

The production method according to claim 16, wherein the increase in the aforementioned expression of the protein derived from the viral vector-producing cell is achieved by addition of an additive to the cell, or by introducing an exogenous plasmid into the viral vector-producing cell.

### Claim 19 (depends on 16)

The production method according to claim 16, wherein the aforementioned protein derived from the viral vector-producing cell is at least one type selected from the group consisting of PIK3C2A, UBE2C, ASNS, NIFK, PDCD4, DDX47, GTPBP4, FTSJ3, DDX49, GNL2, NAT10, UBL5, SERBP1, and NOVA2.

### Claim 20 (depends on 14)

The production method according to claim 14, wherein the regulation is to decrease the aforementioned expression of the protein derived from the viral vector-producing cell as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in the HEK293 cell (Accession number ATCC CRL1573).

### Claim 21 (depends on 20)

The production method according to claim 20, wherein the regulation is to decrease the aforementioned expression of the protein derived from the viral vector-producing cell by not less than 10% at the time of viral vector production, as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in the HEK293 cell (Accession number ATCC CRL1573).

### Claim 22 (depends on 20)

The production according to claim 20, wherein the decrease in the aforementioned expression of the protein derived from the viral vector-producing cell is achieved by addition of an additive to the cell, or by introducing an exogenous plasmid into the viral vector-producing cell.

### Claim 23 (depends on 20)

The production method according to claim 20, wherein the aforementioned protein derived from viral vector-producing cell is at least one type selected from the group consisting of ISG15, CD44, LMNA, ACP2 and MRE11.

### Claim 24 (depends on 14)

The production method according to claim 14, wherein the cell is derived from an animal cell.

### Claim 25 (depends on 24)

The viral vector-producing cell according to claim 24, wherein the aforementioned human cell is HEK293 cell.

### Claim 26 (depends on 14)

The production method according to claim 14, wherein the aforementioned viral vector is an adeno-associated viral vector.

### Claim 27

A method for enhancing a production amount of a viral vector in a viral vector-producing cell, comprising regulating expression of a protein derived from the viral vector-producing cell in the viral vector-producing cell.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the regulation is performed by comparison with the viral vector-producing cell before regulation of the expression of the aforementioned protein, or with HEK293 cell (Accession number ATCC CRL1573).

### Claim 29 (depends on 27)

The method according to claim 27, wherein the regulation is to increase the aforementioned expression of the protein derived from the viral vector-producing cell as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or with HEK293 cell (Accession number ATCC CRL1573).

### Claim 30 (depends on 29)

The method according to claim 29, wherein the increase in the aforementioned expression of the protein derived from the viral vector-producing cell is achieved by addition of an additive to the cell, or by introducing an exogenous plasmid into the viral vector-producing cell.

### Claim 31 (depends on 27)

The method according to claim 27, wherein the regulation is to decrease the aforementioned expression of the protein derived from the viral vector-producing cell as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in the HEK293 cell (Accession number ATCC CRL1573).

### Claim 32 (depends on 31)

The method according to claim 31, wherein the decrease in the aforementioned expression of the protein derived from the viral vector-producing cell is achieved by addition of an additive to the cell, or by introducing an exogenous plasmid into the viral vector-producing cell.

### Claim 33

A method for selecting a viral vector-producing cell with an improved ability to produce vectors, comprising a step of selecting a cell in which the expression of a protein derived from the viral vector-producing cell is regulated in the viral vector-producing cell.

### Claim 34 (depends on 33)

The method according to claim 33, comprising a step of selecting a cell in which expression of the protein derived from the viral vector-producing cell is regulated in the viral vector-producing cells as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in HEK293 cell (Accession number ATCC CRL1573).

### Claim 35 (depends on 33)

The method according to claim 33, wherein the regulation is performed to increase the expression as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in HEK293 cell (Accession number ATCC CRL1573).

### Claim 36 (depends on 33)

The method according to claim 33, wherein the regulation is performed to decrease the aforementioned expression of the protein derived from the viral vector-producing cell as compared with that in the viral vector-producing cell before regulation of the expression of the aforementioned protein, or that in HEK293 cell (Accession number ATCC CRL1573).

### Claim 37 (depends on 36)

The method according to claim 36, wherein the protein derived from the aforementioned viral vector-producing cells is CD44.
